GQ1005

GQ1005 is an antibody-drug conjugate developed by GeneQuantum Healthcare (Suzhou). Its target is HER2 (the sponsor names HER2). The sponsor states: A HER2-targeting antibody-drug conjugate using a cleavable open-ring linker and a Topoisomerase I inhibitor payload. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07673029 (A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer), in HER2-positive breast cancer. The largest, NCT07673029, plans to enrol 228 participants with primary completion expected 2027-01-09. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.